1 Tsuchiya K,Asahina Y,Matsuda S,et al.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma[J]. Cancer,2014,120(2):229-237. 2 Sullivan LA,Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition [J]. MAbs,2010,2(2):165-175. 3 Lee D,Chung YH,Kim JA,et al.Vascular endothelial growth factor may be a useful predictor of response to combined therapy with sorafenib and transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology International,2014,8(5):S276-S277. 4 朱芳,李振宇,任精华,等. VEGF与肿瘤血管生成拟态的研究[J]. 临床肿瘤学杂志,2009,14(1):20-24. 5 Cao GC,Li XY,Qin C,et al. Prognostic value of VEGF in hepatocellular carcinoma patients treated with sorafenib:A meta-analysis[J]. Med Sci Monit,2015,21:3144-3151. 6 Giaccia A,Siim BG,Johnson RS. HIF-1 as a target for drugdevelopment[J]. Nat Rev Drug Discov,2003,2(10):803-811. 7 Ferrara N. VEGF and quest for tumor angiogenesis factors[J]. Nat Rev Cancer,2002,2(10):795-803. 8 Amano H,Kato S,Ito Y,et al.The Role of Vascular Endothelial Growth Factor Receptor-1 Signaling in the Recovery from Ischemia[J].PLoS One,2015,10(7):1-18. 9 Legros L,Guilhot J,Huault S,et al. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib[J]. Leuk Res,2014,38(6):662-665. 10 Chen H,Shen YF,Gong F,et al.Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia[J].European Review for Medical and Pharmacological Sciences,2015,19(19):3569-3573. 11 张广宇,赵敏,徐明堂,等.血管内皮生长因子及其受体与肺癌血管新生的研究[J].中华结核和呼吸杂志,2002,25(2):89-93. 12 陈公琰,洪璇.血管内皮生长因子与肺癌的关系[J].中华肿瘤杂志,2005,27(8):449-451. 13 Andrew P,Levy NS,Loscalzo J,et al. Regulation of VEGF incardiac myocytes[J]. Circulation,1995,76(5):758-766 |